- Early trials of a vaccine that targets a specific gene found in tumors, known as KRAS, has proven to be effective in 84% of patients who had pancreatic or colorectal cancers recur after their initial treatment.
- Biotech company Orbis Health Solutions was approved to begin a phase 3 clinical trial of its melanoma vaccine.
- Results from a phase 2 trial found a drug-vaccine combination developed by Merck and Moderna cut the risk of recurrence or death in patients with severe melanomas by 49%.
- A breast cancer vaccine has shown promise in a phase 1 trial spearheaded by researchers at the Seattle-based University of Washington’s Cancer Vaccine Institute and is preparing to move to phase 2.
- A new vaccine, called SurVaxM, that fights the deadliest form of brain cancer, glioblastoma, has shown promise in early trials.
- A small, phase 1 study found promising results for a pancreatic cancer vaccine.
6 cancer vaccines showing promise
Here are six cancer vaccines showing promise or in development since May 2023:
From repetitive to real-time: AI that lightens the back-office load
Recommended Live Webinar on Jan 22, 2026 12:00 PM - 1:00 PM CST